PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Upcoming Events

NexGen Biomed 23.01.25
PFS & Injectable drug devices west coast
PFS & Injectable Drug Devices East Cost
AI in Drug Discovery
Bio Trinity
Anglo Nordic

Advertisement

A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
Light Cast – 17.07.2025
QMB Innovation Centre

Exploring the 505(b)(2) Route for Systemic and Regional Therapy via Pulmonary Delivery

The Advantages of Using Respirable Engineered Spray-dried Dry Powder

Inhaled drug products offer several advantages over other dosage forms, including more targeted drug delivery, which can mean a lower dose is required, in turn reducing side-effects. Developing generic versions of complex products is increasingly challenging and it is important to consider a regulatory strategy to achieve market approval as quickly and efficiently as possible, using a simple and efficient pathway. In this article,  Aditya R. Das at Recipharm explores the use of the 505(b)(2) application route to advance inhalation drugs to market and the advantages of using respirable engineered spray-dried powder for the development of these products.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/Exploring-the-505b2-route-for.pdf” width=”100%” height=”900px” style=”border:0;”]

Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
Crown Bioscience 08.09.2025
Polypure hompage